India · Delayed Price · Currency is INR Poly Medicure Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw a strategic pivot to high-tech segments, 12.3% consolidated revenue growth, and strong margin performance despite raw material and logistics headwinds. FY 2027 guidance targets 23–25% consolidated EBITDA margin and 20%+ growth in key segments.
-
Q3 FY26 saw 16.4% YoY revenue growth, strong gross margins, and robust domestic and international expansion, driven by acquisitions and new product launches. Guidance for FY27 targets 20%+ consolidated revenue growth, with continued margin strength and significant CapEx for capacity expansion.
-
Revenue grew 5.7% YoY in Q2 and 5.3% in H1, with strong domestic growth and sequential recovery in international markets. Two acquisitions are set to add INR 280 crore annual revenue, while margin guidance remains at 25%-27%. FY26 revenue growth is now guided at 15%-16%.
-
Q1 FY26 saw 5% revenue growth, strong gross margins, and robust domestic expansion, while international growth guidance was revised down due to global headwinds. New product launches, capacity expansions, and strategic hires position the business for continued leadership.
Fiscal Year 2025
-
The acquisition secures a leading position in the orthopedic trauma and extremity market, with CTFE's strong product portfolio and direct sales presence in key geographies. The deal is valued at €31 million enterprise value, with significant growth and synergy potential, especially through portfolio expansion and leveraging global distribution.
-
The acquisition of a European cardiology business supports global expansion, offering high-margin products, regulatory approvals, and significant synergy potential. Integration will consolidate operations, improve efficiency, and enable faster product launches in regulated markets.
-
Q4 and FY25 saw strong revenue and margin growth, with annual revenue up 21.5% and EBITDA margin at 27.1%. FY26 guidance targets 20% revenue growth, led by robust domestic and retail expansion, while export growth is conservatively guided amid global uncertainties.
-
Q3 FY25 saw 24.9% revenue growth and improved margins, with strong performance in infusion and renal segments. CapEx and new product launches are on track, and guidance for 20%+ growth and margin expansion remains intact. Exports and domestic business both contribute to robust outlook.
-
Revenue grew 23% in H1 FY25, with EBITDA margin rising to 28.06% and PAT up to INR 87.22 crores. Export business remains robust, domestic growth rebounded to 22% in Q2, and new capacity plus QIP-funded expansion positions the company for continued 22%-24% annual growth.
-
Q1 FY25 saw 20% revenue and EBITDA growth, with exports now 70% of sales and strong gains in renal, cardiology, and critical care segments. Capacity expansion and new plants support 22%-24% annual growth guidance, while CapEx and margin improvements remain on track.